Russia's Gamaleya Centre will begin human trials for a personalised mRNA vaccine for melanoma by September-October 2025. This vaccine is tailored using AI to teach the immune system to fight cancer cells. The process analyses a patient's tumour DNA and creates the vaccine in approximately a week. Preclinical results look promising as the vaccine slowed down tumour growth, researchers stated.